Trial · NCT03514420
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 54
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hot flush | Vascular disorders | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Albumin urine present | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 3 | 4 | |
| other | Antinuclear antibody positive | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Gamma-glutamyltransferase increased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 2 | 4 | |
| other | Hepatic steatosis | Hepatobiliary disorders | AKCEA-ANGPTL3-LRx 20 mg | 2 | 4 | |
| other | Blood magnesium decreased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 3 | 4 | |
| other | Creatinine urine increased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Abdominal pain upper | Gastrointestinal disorders | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Diarrhoea | Gastrointestinal disorders | AKCEA-ANGPTL3-LRx 20 mg | 2 | 4 | |
| other | Myalgia | Musculoskeletal and connective tissue disorders | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Blood bilirubin increased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Fatigue | General disorders | AKCEA-ANGPTL3-LRx 20 mg | 2 | 4 | |
| other | Hypoglycaemia | Metabolism and nutrition disorders | AKCEA-ANGPTL3-LRx 20 mg | 2 | 4 | |
| other | Abdominal discomfort | Gastrointestinal disorders | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | International normalised ratio increased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Blood glucose increased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Glycosylated haemoglobin increased | Investigations | AKCEA-ANGPTL3-LRx 20 mg | 2 | 4 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Conjunctivitis | Infections and infestations | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 | |
| other | Arthritis | Musculoskeletal and connective tissue disorders | AKCEA-ANGPTL3-LRx 20 mg | 1 | 4 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03514420/events